Michael J. Fox Foundation backs Rhythm's drug candidate

09/11/2013 | American City Business Journals

The Michael J. Fox Foundation for Parkinson's Research awarded Rhythm Pharmaceuticals a $1.4 million grant to support a midstage study of ghrelin agonist RM-131, its drug candidate for refractory constipation, which affects many Parkinson's disease patients. "As we continue our work to advance RM-131 in the clinic, we are excited to join with The Michael J. Fox Foundation to address this important unmet need in Parkinson’s disease," Rhythm CEO Keith Gottesdiener said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD